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Background: Mucopolysaccharidosis type VI (MPS VI) is a progressive, chronic and multisystem lysosomal
storage disease with a wide disease spectrum. Clinical and biochemical improvements have been reported
for MPS VI patients on enzyme replacement therapy (ERT) with rhASB (recombinant human arylsulfatase
B; galsulfase, Naglazyme®, BioMarin Pharmaceutical Inc.), making early diagnosis and intervention im-
perative for optimal patient outcomes. Few studies have included children younger than ﬁve years of
age. This report describes 34 MPS VI patients that started treatment with galsulfase before ﬁve years of
age.
Methods: Data from patients who initiated treatment at b5 years of age were collected from patients'
medical records. Baseline and follow-up assessments of common symptoms that led to diagnosis and
that were used to evaluate disease progression and treatment efﬁcacy were evaluated.
Results: A signiﬁcant negative correlation was seen with treatment with ERT and urinary GAG levels. Of
those with baseline and follow-up growth data, 47% remained on their pre-treatment growth curve or
moved to a higher percentile after treatment. Of the 9 patients with baseline and follow-up sleep studies,
5 remained unaffected and 1 patient initially with mild sleep apnea showed improvement. Data regard-
ing cardiac, ophthalmic, central nervous system, hearing, surgical interventions and development are
also reported. No patient discontinued treatment due to an adverse event and all that were treatment-
emergent resolved.
Conclusions: The prescribed dosage of 1 mg/kg IV weekly with galsulfase ERT is shown to be safe and effec-
tive in slowing and/or improving certain aspects of the disease, although patients should be closely moni-
tored for complications associated with the natural history of the disease, especially cardiac valve
involvement and spinal cord compression. A long-term follow-up investigation of this group of childrena, Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira/ Fiocruz, Rio de Janeiro, RJ, Brazil,
-020, Brazil.
enetica.com.br (D.D.G. Horovitz).
NC-ND license.
63D.D.G. Horovitz et al. / Molecular Genetics and Metabolism 109 (2013) 62–69will provide further information on the beneﬁts of early treatment as well as disease progression and treat-
ment efﬁcacy and safety in this young patient population.© 2013 Elsevier Inc. Open access under CC BY-NC-ND license.Table 1
ERT-related adverse events presented in the sample.
Adverse event Number of events Number of patients
Pyrexia 3 2
Chills 1 1
Skin rash 1 1
Cyanosis 1 1
Nausea 3 2
Coughing crisis 2 1
Hypertension 1 1
Tachycardia 1 11. Introduction
Mucopolysaccharidosis type VI (MPS VI; OMIM ID: #253200,
Maroteaux-Lamy syndrome) is a lysosomal storage disease inwhichde-
ﬁcient activity of the enzyme N-acetylgalactosamine 4-sulfatase
(arylsulfatase B) impairs the stepwise degradation of the glycosamino-
glycan (GAG) dermatan sulfate [1]. Partially degraded GAGaccumulates
in lysosomes in a wide range of tissues, causing amultisystemic chronic
and progressive disorder with signiﬁcant functional impairment and
shortened lifespan [2,3]. MPS VI has a wide disease spectrum, with rap-
idly progressing patients generally presenting with coarse facies, short
stature and dysostosis multiplex within the ﬁrst year of life. Patients
with more slowly progressing disease may not present with these clas-
sic symptoms, potentially delaying diagnosis until later in life.
Since the advent of enzyme replacement therapy (ERT) for MPS VI
with recombinant human N-acetylgalactosamine 4-sulfatase, rhASB
(galsulfase, Naglazyme®), several aspects of clinical improvement
were reported [3–6]. However, published clinical studies that showed
the efﬁcacy and safety of enzyme replacement therapy for MPS VI
with rhASB did not include younger children (less than 5 years).
This may be due to the challenge of evaluating this age group using
the deﬁned clinical end-points such as the 12-minutes-walk test
(MWT) and pulmonary evaluations, which require the children's un-
derstanding and cooperation.
In the initial clinical trials, ages in Phase I ranged from 7 to 16 years.
In Phase II, ages were from 6 to 22 years and in the Phase III study the
inclusion criteria speciﬁed patients to be at least 5 years of age [4–6]. Al-
though signiﬁcant clinical responses were observed in those trials, long
standing organ damage could not be reversed by ERT, suggesting that
early initiation of therapy could be the best treatment approach. This
was demonstrated in some pre-clinical studies with MPS VI animal
models treated since birth [7], yet there are only a few reports of imple-
mentation of ERT at an early age in MPS VI patients [8,9].
In one report, a pair of MPS VI siblings started galsulfase ERT at
41 months of age and at 8 weeks [8]. As compared to the older sibling
at the same age, the younger sibling developed only mild symptoms
(skeletal, corneal clouding and mitral valve dysplasia), demonstrating
the beneﬁts and safety of early treatment. This report also highlighted
the older sister's outcome, with improvement in skeletal involve-
ment, hepatosplenomegaly and joint mobility [8]. Similar ﬁndings in
another sibling pair were recently reported comparing a 5.6 year-old
boy and his 6 week-old sister [9]. Visual acuity has also been found to
stabilize in 6 MPS VI patients on ERT [10]. Signiﬁcant clinical improve-
ment was shown even in a 3-year-old patient with severe disease
who had to be managed for infusion associated events (IARs) and
yet ERT was not discontinued [11]. However, to ensure that ERT can
be safely initiated at an early age, it is important for physicians to be-
come aware of all symptoms of MPS VI, even those that are not as
clearly indicative of the disease.
As a number of our patients with MPS VI initiated ERT with rhASB
before ﬁve years of age, we sought to determine common presenting
features of these patients, as well as clinical outcomes post-ERT to
provide clinical information regarding use of ERT in this young cohort
of patients.
2. Methods
TheNationalMPS Patient Association –AliançaMPS Brasil– provided
the location of patients with MPS VI in Brazil and their physicians. A
questionnaire (Supplementary Table 1) was developed and sent tothese attending physicians at reference centers for diagnosis and treat-
ment of MPS in Brazil. Data were collected from patients' medical re-
cords after informed consent was obtained. Mean, median and range
of reduction of uKS levels were calculated. Growth velocity was calcu-
lated and percentiles were charted. Disease progression was evaluated
based on cardiac and central nervous system involvement, sleep study
assessments and surgical interventions required for thosewith baseline
and post-ERT assessment. Ophthalmic, developmental and hearing as-
sessments were also evaluated at different time points throughout the
review.
3. Results
Fifteen sites located in the ﬁve different regions of Brazil agreed to
participate. 161 MPS VI patients were identiﬁed in Brazil; 144 (89%)
of which have been on ERT. Of these, 58 (40%) patients started infusions
before the age of ﬁve years, and 34 (59%) of this group agreed to be in-
cluded in this survey. Although 21were boys and only 13were girls, the
1.6:1 sex ratio was not considered signiﬁcant (p > 0.05). Parental con-
sanguinity was present in 18 (60%) of the 30 families involved. MPS VI
clinical signs and symptoms were observed at baseline in all but the
newborn patient (Table 1). Clinical and/or radiological evaluations
were available for 32 patients, with dysostosis multiplex present in
31. No obvious skeletal abnormalities were seen on the newborn
patient's skeletal survey, but no lateral thoraco-lumbar spine ﬁlms
were available for analysis. Some clinical information and additional
exams were not available for all patients.
The median age of diagnosis was 28.5 months. One boy was diag-
nosed prenatally; the earliest postnatal diagnosis was at two months
of age and the latest at 46 months of age. The youngest patient to
start ERT was ﬁve days old, and the oldest, 58 months (Table 2).
3.1. Genotype data
Targeted mutation analysis for known mutations in the ASB gene
was available for 12 patients. Six patients, from the same geographic
location, were homozygous for a previously described pathogenic
mutation, p.H178L [12]. Four patients had a common polymorphism
on intron 3 (IVS3-22 T > C); two patients had none of these common
mutations detected. Sequence analysis of ASB gene is currently in
process.
3.2. GAG levels
All patients had been receiving weekly 1 mg/kg body weight of
galsulfase intravenously, from 1 to 56 months (average 25.47; SD
13.17; median 29.50 months). Only ﬁve patients had been treated for
Table 2
Ages of patients at the time of diagnosis, ERT initiation and present age in MPS VI pa-
tients under ﬁve years of age.
Age at diagnosis
(months)a
Age at 1st ERT
(months)a
Present age (months)
All Boys Girls All Boys Girls All Boys Girls
N 34b 21b 13 34b 21b 13 33b 21b 12
Average 25.94 24.75 27.85 35.06 35.66 34.08 59.88 59.24 61.00
SD 12.94 12.27 14.24 14.97 15.84 14.00 17.93 18.51 17.62
Median 28.50 29.00 28.00 38.50 40.70 35.00 62 64.00 56.50
Min −2.00 −2.00 6.00 0.17 0.17 10.00 24.00 24.00 30.00
Max 46.00 40.00 46.00 58.00 58.00 53.00 90.00 87.00 90.00
a Includes a deceased patient.
b Includes 1 boy who was diagnosed prenatally.
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17 missed b10%, eight between 10 to 20%, and 3 missed >20% (Fig. 1).
Baseline urinary GAG levels were available for 26 of the 34 patients.
They were elevated when compared to normal values for age with an
average of 553.35, SD 452.63, median 516.00 mcg GAG/mg creatinine;
normal values range from 16 to 188 mcg GAG/mg creatinine [13]. A sig-
niﬁcant negative correlation was seen with urinary GAG levels and age
at baseline (r = −0.46; t = 2.538; p b 0.05).
For 11 patients with follow-up urinary GAG levels, 10 had reached
normal levels and one patient, whose baseline GAG excretion was
only slightly raised, remained stable with ERT. Length of treatment
with ERT in this group of patients varied from 15 to 41 months.3.3. Growth
Follow up growth data was available for 32 patients. Mean annual
growth velocity in boys was 5.72 cm (median 4.65 with a range of 0.72
to 12.40 cm) and, in girls, 4.80 cm (median 4.87 with a range of 1.35 to0 50 100
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Fig. 1. Compliance to galsulfase ERT for 34 MPS VI patients und8.50 cm).Mean baseline height z-scorewas−1.76 for thewhole patient
population studied, compared with −0.914 in the ≤2 years old group
and −2.033 in the >2 years population. Baseline height for 20 boys
ranged from 49 to 94.5 cm (median 88; average 84.13; SD 11.4) and
for 12 girls 69.5 to 91.5 cm (median 88.5; average 84.85; SD 7.55)
(Fig. 2). Seventeen of 32 (53.13%) patients (10 boys and 7 girls) were
below the 3rd percentile for height, one girl was above the 97th percen-
tile (Figs. 3, 4a and b). Short stature at baseline was present in only one
patient under 2 years of age, but was present in 21 of 25 patients
above the age of 2 years (Fisher Exact Probability = 0.014). Comparing
baseline to present height data, 12 (37.5%) patients remained on the
same growth curve, 3 (9.4%) went to a percentile curve above and 17
(53%) fell below their original percentile curve (Fig. 2).
Baseline weight ranged from 2.88 to 23 kg for boys and from 7.89
to 17.7 kg for girls. At baseline, 6 of 32 (18.75%) patients (3 boys and
3 girls) were below the 3rd percentile for weight and two patients
(6.25%), a boy and a girl, were above the 97th percentile.
No patient under two years of age was underweight, while 6 of 25
patients above age two were below the 3rd percentile. No signiﬁcant
difference in frequency of underweight patients were found between
the two groups (Fisher Exact Probability = 0.20). Comparing baseline
and presentweight data, 10 patients remained on the sameweight per-
centile curve, 7 had increased to a higher percentile curve and 15
dropped to a lower percentile. Weight gain during treatment ranged
in boys from 500 g to 13 kg and in girls from 1.3 to 6.3 kg. The median
monthly gain for boys was 277 g (average 161; SD 98 g) and ranged
from 45 g to 361 g. The median monthly gain for the girls was 146 g
(average 133 g; SD 44 g) and varied from 54 to 200 g.
At baseline, 7 out of 30 patients (5 boys and 2 girls) had a head cir-
cumference (HC) above two standard deviations, 2 of these have now
normal measurements for age and 5 continued on the same percentile
curve. Two patients had HC less than two standard deviations at base-
line and on follow-up, one is within normal standards for age and the
other is slightly below. Three of the 20 patients, that had normal mea-
surements at baseline, had HC two standard deviations above at
follow-up.150 200 250
Number of infusions received
Number of missed infusions
er ﬁve years of age, ordered by total weeks on treatment.
84.12
95.72
84.85
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Fig. 2. Mean ± SD baseline and present height (absolute measurement distribution)
for 32 MPS VI patients, 20 boys and 12 girls who had ERT introduced before ﬁve
years of age.
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No severe infusion-related reactions were observed. Despite the
occurrence of adverse events (AE) considered treatment-related in
8 (24%) patients, all continued to receive infusions without further
complications. During an infusion, one patient who had been on ERT
for two years presented with skin rash and local edema (in the con-
tralateral limb of the infusion site). This type of reaction persisted
for 12 weeks, and was controlled with oral and intravenous antihista-
mines and intravenous steroids; he is now being pre-medicated with
intravenous antihistamines before each infusion.
Four patients had one episode of mild AEs each (rise in blood
pressure, tachycardia, skin rash and nausea), and the youngest pa-
tient (a neonate) had one episode of pyrexia with cyanosis. This ep-
isode resolved once infusion was halted and did not recur once
infusion was restarted at a slower rate. Two patients presented
with the same mild AE on 2 occasions (one had a coughing crisis
with post-tussive emesis and the other developed transient pyrexia
and shivering). Decreasing the rate of infusion and antipyretics
were sufﬁcient to control those AEs. The 34 patients had a total of
3325 galsulfase infusions in which 21 AEs were reported. (Table 3)
One (3%) patient died from pulmonary hypertension at 6 years of
age which was deemed not related to treatment.
3.5. Heart involvement
Of the 28 patients with baseline echocardiogram (echo) assessments,
18 (64%) had an abnormal echo; 7 had left ventricular hypertrophy (LVH)
without ventricular dysfunction. Valve abnormalitieswere observed in 17
patients (mitral: 13; aortic: 6; tricuspid: 2). Aortic root dilatation was
found in 2 patients. Twelve patients who had been on ERT for at least0
5
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Fig. 3. Baseline and present height percentiles for 32 MPS VI patients, 20 boys and 12
girls who had ERT introduced before ﬁve years of age.17 months had more than one follow-up echo exams. Valvular disease
worsened in 11 patients, while the remaining showed no change. LVH
improved in 4 patients over the treatment period, while 3 patients did
not show further worsening. One patient had mitral valve regurgitation
on diagnosis and severe pulmonary hypertension with dilated right
chambers, severe right ventricular dysfunction and right to left oval fora-
men shunt upon follow-up. This patient died at six years of age due to
pulmonary hypertension, considered not related to treatment.
The other 10 patients had normal echos at baseline. Two of these
10 remained normal on follow-up exam: the patient who started
ERT as a neonate had normal echos at baseline and at follow-up at
27 months of age; the other patient that had a normal follow-up
echo at 41 months of age started ERT when he was 26 months-old.
One patient's echo at four months of age showed ductus arteriosus,
while follow up exam at 23 months of age (17 months on ERT)
showed mild mitral valve regurgitation, left ventricular and atrial di-
latation with normal function. The other seven patients developed
mitral regurgitation, three associated with aortic regurgitation and
one with tricuspid regurgitation, and three of these patients also
showed LVH. Among the six patients without a baseline echo, four
were evaluated during treatment and all presented with mitral regur-
gitation, one combined with LVH. The remaining two patients had
heart murmurs but have yet to be examined. In summary, when
reviewing the most recent assessment of the 32 patients with an echo
evaluation performed at any time, only two had normal exams, 30
had valve involvement and 11 had LVH.
3.6. Central nervous system, spinal cord and nerve conduction
Neuroimaging was undertaken in 11 patients: 5 had brain CT and
6 had brain MRI. Among those, 5 were reported as normal, 5 showed
signs of hydrocephalus, 2 of these with white matter lesions and one
was diagnosed as having brain atrophy. Two patients had measure-
ment of intracranial pressure (ICP). One patient had elevated ICP
and a ventricle-peritoneal shunt was placed.
Six patients underwent cervical MRI: 4 showed spinal cord com-
pression at the cervical level and 2 of them had T2-hypersignal
suggesting myelopathy. These patients had clinical signs of compres-
sion, with motor and sensitive deﬁcits, 2 already at baseline and 2 de-
veloped clinical signs of compression during follow-up. The other 2
patients had reduction of intravertebral space, 1 with atlantoaxial in-
stability, but with no clinical or radiological signs of compression or
myelopathy.
One patient in the cohort became paraplegic after a fall; unfortu-
nately the cause has not yet been clariﬁed, since no MRI has been
performed. Three patients underwent neurophysiologic evaluations
(SSEP, MEP and electroneuromyography), compatible with spinal cord
compression at the cervical level, and one had a conﬁrmation of bilater-
al carpal tunnel syndrome.
3.7. Surgery
Fourteen patients underwent a total of 18 surgical procedures: 8
for hernia repair (2 had recurrent hernia), 4 for cervical spinal cord
decompression and one for carpal tunnel syndrome. One patient
had an adenoidectomy, one had clubfoot surgical correction and one
had a thoracic tube inserted due to pleural effusion. Six of these pro-
cedures were performed even before MPS was diagnosed, and one
after diagnosis but before the patient began ERT. Two patients had in-
fusion catheter implantation for administration of ERT.
3.8. Sleep studies
Sleep studies were performed at baseline in 17 patients, with
follow-up studies available for 9 patients. At baseline, 12 of those
assessed showed sleep apnea while the rest were unaffected. Of the
Fig. 4. A and B. Absolute present height (cm) of MPS VI patients compared to the World Health Organization (WHO) percentiles.
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sleep studies remained unchanged. One patient with severe sleep
apnea at baseline remained stable. Interestingly, one patient withmild apnea showed improvement with a normal follow-up study.
Nevertheless, two patients had progression of sleep apnea from nor-
mal/mild to severe.
Table 3
Frequency of reported cardinal clinical signs at baseline evaluation for 34 MPS VI pa-
tients on ERT under ﬁve years of age.
Cardinal baseline signsa Frequency of patientsb
Dysostosis multiplex 31/32
Coarse facies. 18/27
Short Stature 17/32
Valvular Disease 17/28
Sleep apnea 12/15
Corneal Clouding 9/15
Auditive deﬁcit 8/12
Head Circumference >2 SD 8/30
Myocardiopathy 7/28
Hydrocephalus 7/11
Motor and/or speech delay 7/33
Cervical spinal cord compression 4/6
a Information or examinations were not available for all patients.
b Number of patients with cardinal base signs out of those with available data.
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Ophthalmologic evaluations were performed in 15 patients at dif-
ferent time points relative to length of time on ERT in the study. Mild
corneal clouding was observed in 9. Intraocular pressure examina-
tions were measured in 4 patients – all of them had normal pressure.
Fundoscopy was performed in only one patient and showed a very
discrete retinal epithelial rarefaction.
3.10. Hearing
Hearing tests were performed at baseline in 11 patients and one
only had it after introduction of ERT; 8 patients had bilateral mild or
moderate conductive deﬁcits. Follow-up studies were only possible
in 3 patients: 1 had a normal evaluation and 2 remained unchanged.
3.11. Development
Out of the 34 patients, 7 had development delay at baseline, one
probably due to perinatal hypoxia. A patient who presented initially
with speech and motor delay had only mild speech delay at last fol-
low up. Adequate motor and language development for age was no-
ticed in 3 unrelated patients with previous features of motor delay
and in 2 other patients with speech delay. Speech delay was observed
in the patient treated since neonatal period at 32 months of age.
4. Discussion
The use of galsulfase in the Brazilian MPS patients with treatment
initiation of b5 years of age in this studywas found to be safe and effec-
tive in this young patient population and similar to that seen in clinical
trials with older patients [4–6]. Diagnosis was conﬁrmed earlier in fam-
ilies with a previously affected child than in those families without a
previously diagnosed child. Among the non-familiar cases, children
were diagnosed only after the onset of clinical symptoms. Early treat-
ment initiation with ERT was introduced under the rationale that no
major contraindications for young patients were reported either in the
literature or on the galsulfase prescribing information. Most physicians
followed published guidelines for treatingMPS VI and assessing disease
progression and treatment efﬁcacy [14].
TheMPS VI patients presented in this report were treated in different
clinical centers; all located within Brazil and were not involved in any
clinical trials. As such, assessments used to assess disease progression
and treatment efﬁcacymayhave differed slightly from those used in clin-
ical trials, and were likely not as stringently implemented as done with
clinical trials. Economic and geographic factors were obstacles for pro-
vidingmore complete evaluations. Some assessmentswere not availablein some settings, such as imaging exams and laboratory evaluations. Sev-
eral exams that required sedation were not performed due to increased
risks in relation to the beneﬁts that would be provided. Furthermore,
many children were too young to perform exams that required their
comprehension and voluntary participation. These factors may result in
variations in assessments used between and within clinics.
Mean baseline uGAG levels were 553.35 SD 452.63, higher that the
338 SD 111 reported by Decker et al. 2010, whereas mean baseline
height z-scorewas−1.76, as compared to the−4.4 reported by Decker
et al. 2010 in a cohort of 5–7 years [15]. Disparity in uGAG levelsmay be
due to the increased severity of disease experienced in many Brazilian
patients, whereas the disparity in height z-scores may illustrate the sig-
niﬁcant impact of disease individuals experience as they age. Although
this is a retrospective study and measurements and evaluations were
done by different physicians and no pre-treatment growth velocity is
available for comparison, the calculated increase in height velocity dur-
ing ERTwas due in part to the treatment and cannot be considered only
as an effect of joint restriction improvement as growth continued de-
spite bone disease. Two patients moved to a higher height percentile
curve and more than half of the patients dropped to a lower percentile,
although still within the normal range, probably due to the limitation of
ERT treatment for the bone disease in this disorder. We can only hy-
pothesize how different these patients would have grown without
ERT. Further follow upwould be needed to determine what percentage
of patients would achieve normal height and if their growth restriction
is less severe than the untreated counterparts.
Frequency of drug-related AEs in these young children were sim-
ilar to those seen in the clinical studies in subjects >5 years of age,
and were isolated episodes of mild infusion reactions that did not re-
quire withdrawal of ERT [4–7]. Only one death occurred in this pa-
tient population, a female patient born to consanguineous parents,
homozygous for the p.H178L mutation and diagnosed at 27 months
of age with dysostosis multiplex, corneal clouding, mitral valve regur-
gitation and severe sleep apnea/hypopnea.
Treatment with ERT was initiated when the patient was 3.5 years
of age. The patient gained weight and grew 14 cm in 33 months. Her
cardiac involvement continued to progress and deteriorate and she
continued to have chronic upper airway infections and severe sleep
apnea/hypopnea throughout the time of treatment. Her last echocar-
diogram showed severe pulmonary hypertension with dilated right
chambers, severe right ventricular dysfunction and right to left oval
foramen shunt. She died from pulmonary hypertension at 6 years of
age, at which time she had been on ERT for three years. However,
she had missed 22% of scheduled infusions due to the distance to
the treatment site. Other factors may have contributed to compliance
problems resulting in missed ERT infusions for this and other pa-
tients, as well as being obstacles for providing complete evaluations.
Common childhood illnesses, such as occurred with this patient,
may be a frequent cause of missed infusions in this young patient
population.
The fact that one patient of our cohort died of cardiorespiratory
complications highlights the importance of close monitoring of cardi-
ac disease in this population, especially as cardiovascular and respira-
tory complications are the main cause of death for MPS VI patients
[1,16]. Cardiac involvement is a common ﬁnding in MPS VI patients,
with almost two thirds of our study population presenting with cardi-
ac valve abnormalities and/or myocardial involvement at baseline.
Careful, ongoing assessment of heart disease is reinforced by the
fact that only 2 patients continued with normal cardiac function at
follow up (including the patient that started ERT in the neonatal peri-
od). In the other 10 patients with follow-up exams available, 6
presented with ventricular hypertrophy or dilatation at baseline,
which was reduced in 4 and did not change in 2. Nevertheless, valvu-
lar disease continued to progress in 7 patients, seemingly not impact-
ed by treatment with ERT. These results were also seen in young MPS
I patients on ERT [16].
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tient diagnosed as a newborn presented with dysostosis multiplex.
Short stature was present in more than half the patients at baseline
and in 84% of patients >2 years, consistent with the natural history
of the disease, with MPS VI patients usually achieving normal heights
until 2–4 years of age and then fall off their growth curves [15]. It is
important to note that only one of 7 patients b2 years of age at diag-
nosis were affected with short stature as this absence of growth re-
striction may delay the diagnosis of MPS VI.
Sleep disturbances and hearingdeﬁcits are probably underdiagnosed
in our cohort since sleep studies and hearing evaluations were available
only in a few of the centers. Still, more than one third of patients had
apnea/hypopnea. This sign should be pursued as a clue to diagnosis, as
with propermanagement hypoxia and even death can be prevented. Al-
though the few follow-up studies were normal or remained unchanged,
no conclusions on the effect of ERT on sleep disturbances or hearing ca-
pacity can be proposed based on our limited patients' data.
Macrocephalywas reported in a fewpatients, as head circumference
was found to be greater than two standard deviations in 8 children, and
continued to increase on follow-up in some of these patients as well as
in several others whowere considered normal at baseline. The data col-
lected does not allow us to diagnose the etiology of the macrocephaly,
as hydrocephalus cannot be excluded in those subjects where neuroim-
aging studies were not performed. For the 3 children whose head cir-
cumferences were normal at baseline and showed a rise on follow-up,
bone dysplasia may be considered as the cause. Familial inﬂuences can-
not be ruled out either, as parental measurements were not recorded.
Although MPS VI is not considered a neuronopathic disease, the
nervous system should be carefully followed and managed, as sec-
ondary lesions due to hydrocephalus, spinal cord or nerve compres-
sion may lead to severe sequelae [1]. Motor development and/or
speech delay was reported in 6 patients (3 had normal neuroimaging
and 3 had no investigation). Development delay can be expected in
chronically ill patients. Children with joint limitations can have
more difﬁculty to walk or to use their hands, which could explain
the delay in some of our MPS VI patients. Interestingly, among the
group of 5 patients that showed signs of hydrocephalus (2 with
white matter lesions), no development delay or cognitive impairment
were diagnosed. Another important symptom to be aware of is the
early occurrence of myelopathy due to spinal cord compression, pre-
senting both at baseline and also at follow-up. Four of 6 patients that
had spinal MRI performed showed increased T2 signal intensity; the
other 2 patients presented reduction of intravertebral space without
any radiological signs of compression, which would most probably
progress. This type of complication is seen most often in older MPS
VI patients [17]. The early occurrence of such manifestations in this
cohort may be related to an apparent increased MPS VI disease sever-
ity in Brazil probably combined with selection bias, due to a lack of di-
agnosis of the less severely affected patients that remain undiagnosed
until older ages [18–20]. Enhanced cervical mobility possibly second-
ary to ERT leading to cervical instability and thus progressing to com-
pression cannot be ruled out as an explanation [18], however one of
the children in this cohort was found to have spinal cord compression
upon diagnosis of MPS VI, potentially due to inadequate head posi-
tioning for intubation during an emergency surgery for intracranial
hypertension at two years of age, before diagnosis, reinforcing the im-
portance of early diagnosis and symptom awareness.
Lack of suspicion for this diagnosis can also lead to these types of
complications. Not all individuals present with the classic symptoms
of MPS VI. In our cohort, one third of the patients did not present with
coarse facies and two thirds had no corneal clouding at baseline, two
signs that could be an alert for the diagnosis. Considering this data,
other early signs of the disease, such as frequent upper airway infec-
tions, joint and bone problems, among others should be considered im-
portant clues that can lead to early diagnosis and should not be
overlooked by pediatricians. With the increased risk during anestheticsfor this patient population combined with the high occurrence of surgi-
cal interventions required, as illustrated by the six patients in this co-
hort who had surgical procedures before MPS VI was suspected,
physician awareness of the signs and symptoms that can lead to diagno-
sis of MPS is imperative before submitting children to anesthetic proce-
dures, aswell as to ensure early initiation of treatment options currently
available for MPS patients.
5. Conclusions
Enzyme replacement therapy with galsulfase in the prescribed dos-
age of 1 mg/kg bodyweight IVweekly has shown to be safe and effective
in slowing progression and/or improving the burden of the disease for
MPS VI in young children. As early treatment initiation results in im-
proved patient outcomes in this young cohort, early recognition of the
more subtle symptoms associated with slowly progressing disease
should be a priority to ensure early diagnosis and treatment initiation.
Patients should continue to be closely monitored, especially regarding
cardiorespiratory involvement and spinal cord compression. Long-term
follow-up of this group of children will provide us further information
on the beneﬁts of early ERT.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ymgme.2013.02.014.
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